Use of tamsulosin (Sonizin®) in the treatment of chronic abacterial prostatitis


Cite item

Full Text

Abstract

The results of treatment of 49 men with chronic abacterial prostatitis are presented. In the first (study) group were included 30 men from the first day of treatment received tamsulosin (Sonizin®) in a dosage of 4 mg daily during the month. The second (control) group included 19 patients who did not receive alpha-adrenoblockers. Patients in both groups have received standard treatment of pancreatitis. Excellent and good results of treatment were observed in 92.6% of patients from the study group in comparison with 66.4% of patients from control group. In the study group also noted a more pronounced decrease in the amount of symptoms. It was concluded that tamsulosin can be recommended for widespread use in the treatment of chronic abacterial prostatitis, and it is the first-line drug for patients with dominated dysuric disorders.

References

  1. Тиктинский О.Л., Михайличенко В.В. Андрология. Спб., 1999. С. 109-223.
  2. Nickel JC. Prostatitis: evolving management strategies. Urol Clin North Am 1999;26(3):737-42.
  3. Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167(3):1363-66.
  4. Lobel B, Rodriguez A. Chronic prostatitis: what we know, what we do not know, and what we should do! World J Urol 2003;21:57-61.
  5. Nickel JC. The use of 1-adrenoreceptor antagonists in lower urinary tract symptoms: Beyond benign prostatic hyperplasia. Urology 2003;62(Suppl.):34-35.
  6. Kirby RS, Lowe D, et al. Intraprostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982;54(3):729-31.
  7. Hellstrom W, Schmidt RA, Lue TF, et al. Neuromuscular dysfunction in nonbacterial prostatitis. Urology 1987;30(1):183-88.
  8. Kaplan SA, Ikeguchie F, Santarosa RP, et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996;47(3):836-39.
  9. Persson BE, Ronquist G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. J Urol 1996;155(3):958-60.
  10. Barbalias GA, Meares EM, Sant GR. Prostatodynia: clinical and urodynamic characteristics. J Urol 1983;130(2):514-17.
  11. Ishigooka M, Nakada T, Hashimoto T, et al. Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate. Urology 2002;59(3):139-43.
  12. Mehik A, Alas P, Nickel J, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 2003;62(2):425-29.
  13. Cheah P, Liong M, Yuen K, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized placebo controlled trial. J Urol 2003;169(2):592-96.
  14. Nickel J, Narayan P, McKay J, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171(2):1594-98.
  15. Alexander RB, Propert KJ, Schaeffer AJ, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind trial. Ann Intern Med 2004;141(2):581-84.
  16. Mishra VC, Browne J, Emberton M. Role of α-blockers in type III prostatitis: a systematic review of the literature. J Urol 2004;171(1):25-30.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies